{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:41:10Z","timestamp":1791009670400,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1888,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jto.0b013e3181f209b9","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T11:29:35Z","timestamp":1285068575000},"page":"S291-S295","source":"Crossref","is-referenced-by-count":48,"special_numbering":"S4","title":["Thymic Tumors: Relevant Molecular Data in the Clinic"],"prefix":"10.1016","volume":"5","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181f209b9_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/JTO.0b013e31818e105c","article-title":"Thymoma: a focus on current therapeutic management","volume":"4","author":"Girard","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib2","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart","first-page":"146","article-title":"WHO histological classification of tumours of the thymus","year":"2004"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib3","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib6","unstructured":"Pao W, Girard N. Beyond EGFR and KRAS mutations in non-small cell lung cancer. Lancet Oncol In press."},{"key":"10.1097\/JTO.0b013e3181f209b9_bib7","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib8","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib10","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8006","article-title":"Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin\/paclitaxel (C\/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)","volume":"27","author":"Fukuoka","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2559.1993.tb01181.x","article-title":"Expression of epidermal and nerve growth factor receptors in human thymus and thymomas","volume":"23","author":"Pescarmona","year":"1993","journal-title":"Histopathology"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jcp.48.5.447","article-title":"Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen","volume":"48","author":"Gilhus","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","volume":"5","author":"Aisner","year":"2010","journal-title":"J Thoracic Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib25","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1158\/1078-0432.CCR-04-1981","article-title":"Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer","volume":"11","author":"Chou","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib30","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43\u20139006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Str\u00f6bel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib40","doi-asserted-by":"crossref","first-page":"e7273","DOI":"10.1371\/journal.pone.0007273","article-title":"High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)","volume":"4","author":"Gong","year":"2009","journal-title":"PLoS One"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib41","doi-asserted-by":"crossref","unstructured":"Girard N, Teruya-Feldstein J, Payabyab EC, et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol In press.","DOI":"10.1097\/JTO.0b013e3181e392a8"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib42","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2008.19.9331","article-title":"Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer","volume":"27","author":"Karp","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib43","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib46","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3599","article-title":"A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results","volume":"26","author":"Isambert","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/02841860802495362","article-title":"Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma","volume":"48","author":"Azad","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib52","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<639::AID-IJC5>3.0.CO;2-Y","article-title":"p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma","volume":"73","author":"Hirabayashi","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181f209b9_bib53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jtcvs.2008.11.048","article-title":"Recurrent intrathoracic thymomas: potential prognostic importance of cell-cycle protein expression","volume":"138","author":"Mineo","year":"2009","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T10:31:53Z","timestamp":1636540313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415326198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1556086415326198"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181f209b9","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}